Airway inflammation and fear: neuroimmune mechanisms and forebrain circuits

气道炎症和恐惧:神经免疫机制和前脑回路

基本信息

  • 批准号:
    10668648
  • 负责人:
  • 金额:
    $ 35.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-08 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY: Effective regulation of fear is essential for optimal mental health. Fear dysregulation is a hallmark of post- traumatic stress disorder (PTSD), a debilitating condition afflicting 22% of combat veterans. Impaired prefrontal cortex (PFC) functioning contributes to fear dysregulation in PTSD. Not all trauma-exposed individuals develop PTSD suggesting pre-trauma risk factors. Elucidating the nature of such factors will help identify novel therapeutics. Recent evidence supports an association between chronic inflammation and PTSD risk. Accordingly, many inflammatory diseases are linked to increased PTSD. Growing evidence supports a strong association between severe asthma and PTSD, however the severe asthma associated factors and mechanisms that regulate PTSD relevant PFC deficits remain unknown. Our published and recent data using unique mouse paradigms of aeroallergen house dust mite (HDM)-induced driven inflammation, show compromised fear extinction only in mice with Th17/IL17A expansion, an effect dependent on IL17A receptor signaling and peripheral IL17A. Importantly, this is accompanied by 1) reduced neuronal activation in the PFC an extinction- regulatory area and 2) microglial/T cell/endothelial alterations within the subfornical organ (SFO), a BBB-devoid area projecting to the PFC. Collectively these observations inform our hypothesis: severe asthma relevant IL- 17A activates a complex, multi-cellular signaling cascade within the SFO which engages the PFC to regulate fear. This hypothesis will be tested in 3 aims. Aim 1 will determine if IL-17A signaling, and Th17 cell activity is necessary and sufficient for HDM-Th17/IL17A driven fear extinction deficits The ability of IL-17A blockade (neutralizing mAb) or Th17 antagonism (small molecule inhibitor) to reverse fear extinction deficits/neuroimmune alterations in mice with Th2/Th17 responses, or recombinant IL17A to induce fear extinction deficits/neuroimmune alterations in mice with Th2 responses will be assessed. Aim 2 will determine if SFO?IL projections are necessary and sufficient for HDM-Th17/IL17A driven fear extinction deficits Using a retroCre-dependent chemogenetic strategy we will inhibit or activate SFO?IL projections to assess effects on fear extinction in HDM treated mice with Th2 versus Th2/Th17A Aim 3 will identify transcriptomic profiles in the SFO and PFC associated with HDM-Th2/Th17 effects and fear Using single-cell RNAseq, the transcriptional profile of SFO and PFC derived cells will be generated with cell-specific signatures of immune cells, glia, endothelial cells and neurons to identify DEGs and signaling pathways uniquely activated in HDM TH2 vs Th2/Th17 mice. Validation and association with HDM-Th2/Th17 effects on fear will be performed using Aim 1/Aim 2 tissue. Impact: Our data reveals a unique core mechanism by which adaptive immune mediators associated with chronic lung inflammation regulate cortical deficits and fear, relevant to mental health. Completion of these studies will broaden our understanding of how peripheral inflammatory mediators modulate brain function and behavior and identify novel risk factors and therapeutic targets for fear-associated pathologies.
项目概要: 有效地调节恐惧对最佳的心理健康至关重要。恐惧失调是后- 创伤性应激障碍(PTSD),一种折磨22%退伍军人的衰弱性疾病。前额叶受损 皮质(PFC)功能有助于PTSD中的恐惧失调。并不是所有的创伤暴露者 创伤后应激障碍提示有创伤前危险因素。阐明这些因素的性质将有助于确定新的 治疗学最近的证据支持慢性炎症和PTSD风险之间的关联。 因此,许多炎症性疾病与PTSD增加有关。越来越多的证据表明, 严重哮喘与创伤后应激障碍之间的关系,但严重哮喘的相关因素和机制 调节PTSD相关PFC缺陷的机制尚不清楚。我们发表的和最近的数据使用独特的鼠标 空气过敏原屋尘螨(HDM)诱导的炎症的范例,显示出妥协的恐惧 仅在Th 17/IL 17 A扩增的小鼠中消退,这是依赖于IL 17 A受体信号传导的作用, 外周血IL 17 A。重要的是,这伴随着1)减少PFC中的神经元激活和灭绝- 调节区和2)穹窿下器官(SFO)内的小胶质细胞/T细胞/内皮细胞改变, 总的来说,这些观察结果为我们的假设提供了依据:严重哮喘相关的IL- 17 A激活SFO内复杂的多细胞信号级联,其参与PFC调节 恐惧这一假设将在3个目标中进行检验。目的1将确定IL-17 A信号传导和Th 17细胞活性是否 是HDM-Th 17/IL 17 A驱动的恐惧消退缺陷的必要和充分条件。 阻断(中和mAb)或Th 17拮抗(小分子抑制剂),以逆转恐惧消退 Th 2/Th 17应答或重组IL 17 A诱导恐惧的小鼠中的免疫缺陷/神经免疫改变 将评估具有Th 2应答的小鼠中的消退缺陷/神经免疫改变。目标2将决定 如果SFO?IL预测对于HDM-Th 17/IL 17 A驱动的恐惧消退缺陷是必要和充分的 使用一个retroCre依赖的化学遗传学策略,我们将抑制或激活SFO?IL预测评估 对HDM处理的小鼠中恐惧消退的影响,其中Th 2与Th 2/Th 17 A的比较 与HDM-Th 2/Th 17效应和恐惧相关的SFO和PFC中的特征 SFO和PFC衍生细胞的转录谱将用免疫细胞化学的细胞特异性特征产生。 细胞、神经胶质细胞、内皮细胞和神经元,以鉴定HDM中唯一激活的DEG和信号通路 TH 2与Th 2/Th 17小鼠。验证和关联HDM-Th 2/Th 17对恐惧的影响将使用 目标1/目标2组织。影响:我们的数据揭示了一种独特的核心机制, 与慢性肺部炎症相关的调节皮质缺陷和恐惧,与心理健康有关。 这些研究的完成将拓宽我们对外周炎症介质如何调节 脑功能和行为,并确定新的风险因素和治疗目标的恐惧相关的病理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian Paul Lewkowich其他文献

Ian Paul Lewkowich的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian Paul Lewkowich', 18)}}的其他基金

Airway inflammation and fear: neuroimmune mechanisms and forebrain circuits
气道炎症和恐惧:神经免疫机制和前脑回路
  • 批准号:
    10677767
  • 财政年份:
    2022
  • 资助金额:
    $ 35.09万
  • 项目类别:
Preconceptual paternal allergen exposure, offspring asthma, and pulmonary gamma/delta T cell function
孕前父亲过敏原暴露、后代哮喘和肺 γ/δ T 细胞功能
  • 批准号:
    10300217
  • 财政年份:
    2021
  • 资助金额:
    $ 35.09万
  • 项目类别:
Preconceptual paternal allergen exposure, offspring asthma, and pulmonary gamma/delta T cell function
孕前父亲过敏原暴露、后代哮喘和肺 γ/δ T 细胞功能
  • 批准号:
    10427457
  • 财政年份:
    2021
  • 资助金额:
    $ 35.09万
  • 项目类别:
Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
  • 批准号:
    10187646
  • 财政年份:
    2020
  • 资助金额:
    $ 35.09万
  • 项目类别:
Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
  • 批准号:
    10405015
  • 财政年份:
    2020
  • 资助金额:
    $ 35.09万
  • 项目类别:
Perinatal Dysbiosis, Lung Development and Asthma
围产期生态失调、肺部发育和哮喘
  • 批准号:
    10625311
  • 财政年份:
    2020
  • 资助金额:
    $ 35.09万
  • 项目类别:
Preconceptual paternal environmental allergen exposure, sperm epigenetics and offspring asthma development
孕前父亲环境过敏原暴露、精子表观遗传学和后代哮喘发展
  • 批准号:
    9980030
  • 财政年份:
    2020
  • 资助金额:
    $ 35.09万
  • 项目类别:
Impact of prenatal HDM exposure in severely asthmatic mothers on offspring asthma
严重哮喘母亲产前暴露于 HDM 对后代哮喘的影响
  • 批准号:
    9243430
  • 财政年份:
    2016
  • 资助金额:
    $ 35.09万
  • 项目类别:
Mechanisms of IL-17A-mediated enhancement of asthma severity
IL-17A 介导的哮喘严重程度增强的机制
  • 批准号:
    8670181
  • 财政年份:
    2014
  • 资助金额:
    $ 35.09万
  • 项目类别:
Mechanisms of IL-17A-mediated enhancement of asthma severity
IL-17A 介导的哮喘严重程度增强的机制
  • 批准号:
    8842705
  • 财政年份:
    2014
  • 资助金额:
    $ 35.09万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 35.09万
  • 项目类别:
    Studentship
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
    Operating Grants
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
    Salary Programs
Mechanistic Study of Inspiratory Training in Childhood Asthma
儿童哮喘吸气训练机制研究
  • 批准号:
    10637048
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 35.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了